CVS Tops Q4 EPS Estimates with $105.7B Revenue, Reaffirms $400B Guidance
CVS reported Q4 adjusted EPS of $1.09 versus the $0.99 consensus, with revenue rising 8.2% to $105.70 billion, driven by a 6.3% increase in prescriptions and Caremark growth. The company reaffirmed 2026 guidance of at least $400 billion revenue and $7.00–$7.20 EPS, though shares fell premarket.
1. Hedge Fund Stake
Billionaire Larry Robbins holds a 13.76% portfolio stake in CVS Health, representing $617.96 million and marking it as his top stock pick.
2. Q4 Financial Results
CVS reported adjusted Q4 EPS of $1.09 versus a $0.99 consensus, with total revenue rising 8.2% year-over-year to $105.70 billion, fueled by a 6.3% increase in prescription volumes and strength in the Caremark pharmacy benefit unit.
3. 2026 Guidance and Market Reaction
Management reaffirmed its 2026 revenue guidance of at least $400 billion and adjusted EPS of $7.00–$7.20, emphasizing execution discipline, while shares declined premarket as investors weighed cost trends in the Aetna insurance unit.
4. Analyst Outlook and Commentary
Analysts trimmed price targets to $90 at Argus and $95 at Bank of America while maintaining Buy ratings, and Jim Cramer highlighted CVS’s dominant retail pharmacy position against competitors and Aetna’s insurance synergy as key long-term drivers.